T-cell agents in the treatment of rheumatoid arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 3, 2010, Pages 162-165

  Solomon, Gary E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GROWTH INHIBITION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MONOTHERAPY; OPPORTUNISTIC INFECTION; REMISSION; RHEUMATOID ARTHRITIS; SYMPTOM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 78449247305     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. ® (package insert) Princeton, New Jersey: Bristol-Myers Squibb; 2009. Available at http://packageinserts.bms. com/pi/pi-orencia.pdf. Accessed August 4, 2010.
2. Westohovens R, Robles M, Nayiager S, et al. Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis treated with abatacept + methotrexate; results from the AGREE trial (abstract) Arthritis Rheum. 2009;60(Suppl 10):638.
3. Genovese MC, Becker J, Schiff M, et al. Abatacept for rheu-matoid arthritis refractory to tumor necrosis factor N Eng J Med. 2005;353:1114-24
4. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. Oct 7 2009;(4):CD007277.
5. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009 Apr;36(4):736-42; Epub 2009 Feb 27.
6. Westhovens R, Dougados M, Hall S, et al. Disease remission, radiographic non-progression and normalization of function achieved at year 1 are sustained long-term in a majority of patients: 5 year outcomes with abatacept in biologic-naïve patients (abstract). Arthritis Rheum. 2009;60(Suppl 10):1689.
7. Kremer JM, Genant HK, Moreland LW, et al. Results of a two year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58(4):953-63.
8. Simon TA, Smitten AL, Franklin J. Malignancies in the rheumatoid arthritis abatacept clinincal development programme: an epidemiologic assessment. Ann Rheum Dis. 2009 68(12):1819-26.
9. Durez P, Bathon J, Becker JC, et. al. Time course of im-provement in ACR core components in patients with early rheumatoid arthritis treated with abatacept and methotrexate. Ann Rheum Dis. 2010;69(Suppl 3):382.
10. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008 Aug;67(8):1096-103.
11. Schiff M, Keiserman MW, Reed DM, et al. An increasing proportion of patients achieve a low disease activity state or remission when switched from infliximab to abatacept regardless of initial infliximab treatment response: results from the ATTEST trial (abstract) Arthritis Rheum. 2009;60 (Suppl 10):1659.
12. Yazuci Y, Reed DM, Rosenblatt L, et al. Number need to treat (NNT) analysis of randomized clinical controlled trials (RCTS) of biologics in methotrexate-naive patients with early rheumatoid arthritis. Ann Rheum Dis. 2009;68(Supp l3):583.
13. Yazici, Y, Swearingen C. Etanercept, adalimumab, and abata-cept combinations with methotrexate have lower odds rates of discontinuation due to adverse events and serious infections compared to infliximab and methotrexate combinations: an analysis of RCT data. Ann Rheum Dis. 2010:69(Suppl 3):509.